Introduction
The association between cancer and venous thrombo-embolic disease (VTE) was first described by Trousseau 140 years ago [26] . Cancer type and extension can facilitate VTE together with other risk factors such as bed confinement, anti-cancer treatments, central venous devices and advanced age [2, 6, 9, 10, 12, 19, 25, 27] . Prevalence of VTE in cancer patients hospitalised for palliative care can be estimated at 10% [22] .
Low molecular weight heparin (LMWH) is the standard treatment for the prevention of VTE during the first weeks after surgery, during immobilization of the lower limb and during acute hospitalisation for congestive heart failure, respiratory insufficiency, infection, rheumatology problems or inflammatory bowel disease [20, 24] . LMWH therapy has also been shown to increase survival of patients with advanced malignancies and a life expectancy superior to 6 months [15, 17] .
In palliative care for cancer patients, primary prophylaxis of VTE has not been proven useful despite the presence of many risk factors in most patients. Decision to administer VTE prophylaxis may thus depend on health professional experience, place of care and patients' preferences [14] . Widely prescribed in acute hospitals, VTE prophylaxis is rarely administered in nursing homes and even less frequently at home, although risk factors are not different for this patient population.
The main objective of palliative care is to improve patients' quality of their remaining lifetime [3, 28] . In this context, prophylactic treatments may also be justified because anticipation of problems is one key to achieve this goal. Such treatments should virtually have no side effects and should decrease the risk of unpleasant complications while avoiding futile investigations. This is the reason why we started the present open prospective randomised study.
Materials and methods
The study was approved by the Ethic and Research Committee of University Hospitals of Geneva. Consecutive cancer patients admitted to the centre of continuous care with an estimated life expectancy inferior to 6 months were eligible. Objectives were to determine the occurrence of VTE, to detect complications and to measure survival time from study entry.
Exclusion criteria
Patients with absence of judgement abilities precluding to sign written informed consent, VTE during the past 6 months, active bleeding, creatinine clearance <20 ml/min, thrombocytopenia <50 G/l, past history of heparin thrombocytopenia, partial thromboplastin time (PTT) >45 s, prothrombin time (TP) <35% and concomitant anti-coagulation treatment on admission were excluded form this study.
Randomisation procedure
Patients were randomised 1:1 with the heparin group receiving LMWH and the control group receiving neither LMWH nor placebo. Sets of 20 sealed envelopes were prepared by one of us (FH) and numbered consecutively. Each envelope contained one YES (LMWH prophylaxis) or NO (no prophylaxis). The sequence of treatments was randomly assigned in blocks of constant size (n=20). There were 10 YES and 10 NO in each block. Envelopes were opened by the principal investigator (CW) to allow treatment allocation. Treatment Nadroparine (Fraxiparine®) was provided by the University Hospitals of Geneva central pharmacy. Dose was 0.3 ml, i.e. 2,850 U of anti-Xa factor for patients <70 kg and 0.4 ml, i.e. 3,800 U of anti-Xa factor for patients >70 kg. Nadroparine was administered once daily as a subcutaneous injection. 
Statistical analysis
A two-group continuity corrected chi-square test with a 0.050 two-sided significance level would have 80% power to detect a difference between a group 1 proportion of 0.0500 and a group 2 proportion of 0.0125 (odds ratio of 0.241) when the sample size in each group would reach 389. After 18 months, only 20 subjects could be enrolled among 157 eligible patients. We thus decided to analyse the results and to submit them for publication. [7] .
Results
Twenty patients were included over a period of 18 months. This represented 13% of the total population of cancer patients admitted for palliative care to our 104-bed hospital with an estimated life expectancy of less than 6 months (Fig. 1) . Low accrual was explained by LMWH contraindication, patients' incompetence to sign informed consent and patients' refusal to participate in the study.
Patients' characteristics
Age varied between 55 and 88 years with a median of 69 years in the control group and of 73.5 years in the group receiving prophylactic nadroparin, but this was not statistically different. There was only one haematology tumour and 19 solid tumours, and all were far advanced and/or widely metastasised cancers. Most were adeno-carcinomas, eight in the nadroparin group and four in the control group. Duration of cancer disease before admission was 30 months in the nadroparin group and 12.5 months in the control group (P=0.075). Mini Mental State [8] and Functional Independence Measure [16] scores were comparable. However, WHO performance status was 3 in the control group and 2 in the group receiving prophylactic nadroparin, and this was statistically different (P=0.029; Tables 1 and 2 ). Events VTE occurred once as both DVT and PE at the same time in a patient receiving prophylactic nadroparin. Major bleeding occurred once as a rectorrhagia in a patient receiving prophylactic nadroparin, and two patients of the control group presented minor bleeding with sputum and diarrhoea (Table 3) . No episodes of thrombocytopenia were recorded either on days 7 and 14 as per protocol or later during the clinical course. Six patients (33%) could be discharged home with five of them in the group receiving prophylactic nadroparin, but the difference was not significant. At 3 months, there was a tendency towards more deaths in the control group with nine patients dying, whereas five died in the group receiving prophylactic nadroparin (P= 0.141). Two patients survived for more than 9 months in the treated group vs 0 in the other group.
The Kaplan-Meier survival curves are shown in Fig. 2 , but there was no statistical difference between the groups according to the log-rank test (P=0.2382). Post hoc power analysis reveals that a Fisher's exact test with a 0.050 two-sided significance level will have 81 and 90% power to detect the difference between a treated group proportion of 0.500 and a control group proportion of 0.900 when the sample size in each group reaches 23 and 29 subjects, respectively.
Discussion
Utility of prophylactic anti-coagulation in palliative care has yet to be demonstrated. The results of our open prospective randomised study did show neither clear benefit for the administration of prophylactic nadroparin nor obvious disadvantages.
More deaths occurred in the control group during the study and may have resulted from undetected VTE. Terminal VTE might thus have occurred, but this hypothesis couldn't be verified because autopsy was not performed.
Patients receiving prophylactic nadroparin had a statistically significant better WHO performance status at inclusion, and 50% of them could be discharged home. Duration of cancer was longer and there were more adenocarcinomas in the nadroparin group, but the difference did not reach statistical significance. Taken together though, these factors may suggest a more indolent course of the disease explaining why a higher level of activity was retained. In addition, mobility, as an indication of both physical and psychological well-being, may be a good protection factor against VTE. We would thus encourage physical exercise in patients capable and willing to maintain activity during the palliative phase of cancer.
Our study included a limited number of patients despite large inclusion criteria confirming the technical difficulties of specific palliative-care research [1, 4, 5, 11, 18, 21] . Inability to give informed consent because of poor general conditions at admission was the main reason for participants' exclusion. Given the recruitment difficulties encountered in our specialised palliative care centre, we would call for the design of multi-institutional collaborative studies to follow on this important subject. Alternatively, palliative-care cancer patients should have earlier access to this research as this may help obtain informed consent at a better time. Finally, the development of supportive care leading towards smoother transition from curative to palliative care may also be an appropriate answer to increase scientific research in favour of this highly vulnerable group of patients.
Practical guidelines based on other types of patients will thus continue to influence the prescription of prophylactic anticoagulation. In this respect, we would like to remind that hospitalisation by itself is not an indication for prophylactic LMWH, whereas immediate post-surgical period and acute medical problems are [13] .
It would thus appear legitimate to prescribe prophylactic LMWH when patients' quality of life is good enough to indicate therapeutic anticoagulation in the case of a VTE event (Fig. 3) . When life expectancy is a matter of days or perhaps even weeks, prophylactic anticoagulation is probably futile since most symptoms can be adequately controlled with other means [4, 14] Palliative care faces great challenges in front of cancer augmentation and aging of the population [23, 29] . On the one hand, our study would suggest absence of a clear demonstration that the administration of prophylactic LMWH is of benefit for advanced cancer patients hospitalised for palliative care. There was, though, a tendency towards less death occurrence during hospitalization, and two participants survived beyond expectation. Previous results have suggested increase survival for cancer patients with a life expectancy of more than 6 months who received LMWH [17] . Our finding may thus contribute to extend LMWH administration to advanced cancer patients with the shortest life expectancy to facilitate home discharge and optimise the utilisation of health resources.
